Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. Dezember 2025 08:00 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
18. November 2025 08:00 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
06. November 2025 08:00 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross...
20. Oktober 2025 08:00 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences to Participate in November Investor Conferences

CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
29. September 2025 08:00 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
24. September 2025 21:15 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences Announces Pricing of Upsized Public Offering

CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
22. September 2025 16:14 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences Announces Proposed Public Offering

CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
22. September 2025 07:00 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in...
19. September 2025 16:18 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
04. September 2025 08:00 ET | Quelle: MBX Biosciences, Inc.

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...

Nächste Seite